BACKGROUND: Compared with serum potassium levels 4-5.5 mEq/L, those <4 mEq/L have been shown to increase mortality in chronic heart failure (HF). Expert opinions suggest that serum potassium levels >5.5 mEq/L may be harmful in HF. However, little is known about the safety of serum potassium 5-5.5 mEq/L. METHODS: Of the 7788 chronic HF patients in the Digitalis Investigation Group trial, 5656 had serum potassium 4-5.5 mEq/L. Of these, 567 had mild hyperkalemia (5-5.5 mEq/L) and 5089 had normokalemia (4-4.9 mEq/L). Propensity scores for mild hyperkalemia were used to assemble a balanced cohort of 548 patients with mild hyperkalemia and 1629 patients with normokalemia. Cox regression models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for association between mild hyperkalemia and mortality during a median follow-up of 38 months. RESULTS: All-cause mortality occurred in 36% and 38% of matched patients with normokalemia and mild hyperkalemia respectively (HR, 1.07; 95% CI, 0.90-1.26; P=0.458). Unadjusted, multivariable-adjusted, and propensity-adjusted HRs for mortality associated with mild hyperkalemia were 1.33 (95% CI, 1.15-1.52; P<0.0001), 1.16 (95% CI, 1.01-1.34; P=0.040) and 1.13 (95% CI, 0.98-1.31; P=0.091) respectively. Mild hyperkalemia had no association with cardiovascular or HF mortality or all-cause or cardiovascular hospitalization. CONCLUSION: Serum potassium 4-4.9 mEq/L is optimal and 5-5.5 mEq/L appears relatively safe in HF. Despite lack of an intrinsic association , the bivariate association of mild-hyperkalemia with mortality suggests that it may be useful as a biomarker of poor prognosis in HF. Published by Elsevier Ireland Ltd.
BACKGROUND: Compared with serum potassium levels 4-5.5 mEq/L, those <4 mEq/L have been shown to increase mortality in chronic heart failure (HF). Expert opinions suggest that serum potassium levels >5.5 mEq/L may be harmful in HF. However, little is known about the safety of serum potassium 5-5.5 mEq/L. METHODS: Of the 7788 chronic HF patients in the Digitalis Investigation Group trial, 5656 had serum potassium 4-5.5 mEq/L. Of these, 567 had mild hyperkalemia (5-5.5 mEq/L) and 5089 had normokalemia (4-4.9 mEq/L). Propensity scores for mild hyperkalemia were used to assemble a balanced cohort of 548 patients with mild hyperkalemia and 1629 patients with normokalemia. Cox regression models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for association between mild hyperkalemia and mortality during a median follow-up of 38 months. RESULTS: All-cause mortality occurred in 36% and 38% of matched patients with normokalemia and mild hyperkalemia respectively (HR, 1.07; 95% CI, 0.90-1.26; P=0.458). Unadjusted, multivariable-adjusted, and propensity-adjusted HRs for mortality associated with mild hyperkalemia were 1.33 (95% CI, 1.15-1.52; P<0.0001), 1.16 (95% CI, 1.01-1.34; P=0.040) and 1.13 (95% CI, 0.98-1.31; P=0.091) respectively. Mild hyperkalemia had no association with cardiovascular or HF mortality or all-cause or cardiovascular hospitalization. CONCLUSION: Serum potassium 4-4.9 mEq/L is optimal and 5-5.5 mEq/L appears relatively safe in HF. Despite lack of an intrinsic association , the bivariate association of mild-hyperkalemia with mortality suggests that it may be useful as a biomarker of poor prognosis in HF. Published by Elsevier Ireland Ltd.
Authors: Sharon Ann Hunt; William T Abraham; Marshall H Chin; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Mariell Jessup; Marvin A Konstam; Donna M Mancini; Keith Michl; John A Oates; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy; Elliott M Antman; Sidney C Smith; Cynthia D Adams; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Jonathan L Halperin; Loren F Hiratzka; Alice K Jacobs; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel Journal: Circulation Date: 2005-09-13 Impact factor: 29.690
Authors: Ali Ahmed; Ahsan Husain; Thomas E Love; Giovanni Gambassi; Louis J Dell'Italia; Gary S Francis; Mihai Gheorghiade; Richard M Allman; Sreelatha Meleth; Robert C Bourge Journal: Eur Heart J Date: 2006-05-18 Impact factor: 29.983
Authors: Anand S Iyer; Mustafa I Ahmed; Gerasimos S Filippatos; O James Ekundayo; Inmaculada B Aban; Thomas E Love; Navin C Nanda; George L Bakris; Gregg C Fonarow; Wilbert S Aronow; Ali Ahmed Journal: J Am Soc Hypertens Date: 2010 Jan-Feb
Authors: Marjan Mujib; Abu-Ahmed Z Rahman; Ravi V Desai; Mustafa I Ahmed; Margaret A Feller; Inmaculada Aban; Thomas E Love; Michel White; Prakash Deedwania; Wilbert S Aronow; Gregg Fonarow; Ali Ahmed Journal: Am J Cardiol Date: 2010-12-22 Impact factor: 2.778
Authors: Phillip H Lam; Daniel J Dooley; Chakradhari Inampudi; Cherinne Arundel; Gregg C Fonarow; Javed Butler; Wen-Chih Wu; Marc R Blackman; Markus S Anker; Prakash Deedwania; Michel White; Sumanth D Prabhu; Charity J Morgan; Thomas E Love; Wilbert S Aronow; Richard M Allman; Ali Ahmed Journal: Int J Cardiol Date: 2016-11-04 Impact factor: 4.164
Authors: Mustafa I Ahmed; Mitja Lainscak; Marjan Mujib; Thomas E Love; Inmaculada Aban; Ileana L Piña; Wilbert S Aronow; Vera Bittner; Ali Ahmed Journal: Int J Cardiol Date: 2009-11-24 Impact factor: 4.164
Authors: Prakash Deedwania; Kanan Patel; Gregg C Fonarow; Ravi V Desai; Yan Zhang; Margaret A Feller; Fernando Ovalle; Thomas E Love; Inmaculada B Aban; Marjan Mujib; Mustafa I Ahmed; Stefan D Anker; Ali Ahmed Journal: Int J Cardiol Date: 2013-05-31 Impact factor: 4.164